GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Shiller PE Ratio

Vericel (Vericel) Shiller PE Ratio : (As of May. 27, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Vericel Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vericel Shiller PE Ratio Historical Data

The historical data trend for Vericel's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Shiller PE Ratio Chart

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vericel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vericel's Shiller PE Ratio

For the Biotechnology subindustry, Vericel's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vericel's Shiller PE Ratio falls into.



Vericel Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vericel's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Vericel's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.08/131.7762*131.7762
=-0.080

Current CPI (Mar. 2024) = 131.7762.

Vericel Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.940 100.560 -1.232
201409 -0.820 100.428 -1.076
201412 -0.170 99.070 -0.226
201503 -0.270 99.621 -0.357
201506 -0.160 100.684 -0.209
201509 -0.260 100.392 -0.341
201512 -0.280 99.792 -0.370
201603 -0.240 100.470 -0.315
201606 -0.220 101.688 -0.285
201609 -0.380 101.861 -0.492
201612 -0.340 101.863 -0.440
201703 -0.310 102.862 -0.397
201706 -0.070 103.349 -0.089
201709 -0.160 104.136 -0.202
201712 0.010 104.011 0.013
201803 -0.210 105.290 -0.263
201806 -0.120 106.317 -0.149
201809 -0.020 106.507 -0.025
201812 0.110 105.998 0.137
201903 -0.070 107.251 -0.086
201906 -0.450 108.070 -0.549
201909 0.070 108.329 0.085
201912 0.200 108.420 0.243
202003 -0.100 108.902 -0.121
202006 -0.180 108.767 -0.218
202009 0.080 109.815 0.096
202012 0.250 109.897 0.300
202103 -0.070 111.754 -0.083
202106 -0.080 114.631 -0.092
202109 -0.110 115.734 -0.125
202112 0.090 117.630 0.101
202203 -0.150 121.301 -0.163
202206 -0.190 125.017 -0.200
202209 -0.140 125.227 -0.147
202212 0.120 125.222 0.126
202303 -0.160 127.348 -0.166
202306 -0.110 128.729 -0.113
202309 -0.080 129.860 -0.081
202312 0.270 129.419 0.275
202403 -0.080 131.776 -0.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vericel  (NAS:VCEL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vericel Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Vericel's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel (Vericel) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp 10 percent owner 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019